Moderna Stock News

Moderna beat Wall Street's revenue and earnings estimates in Q4. The company was helped by deferred revenue from Gavi, the Vaccine Alliance, and an income tax benefit.

Moderna (MRNA) came out with quarterly earnings of $0.55 per share, beating the Zacks Consensus Estimate of a loss of $0.78 per share. This compares to earnings of $3.61 per share a year ago.

Moderna reported a profit of 55 cents a share on revenue of $2.8 billion in the December quarter, beating analysts' expectations.

Moderna reiterated its full-year 2024 sales guidance of roughly $4 billion.

Moderna on Thursday reported a surprise fourth-quarter profit helped by cost cutting and some deferred payments, and the vaccine maker set out a commercial roadmap for its experimental respiratory syn

Let us take a look at what's in store for biotech/drug stocks MRNA, BHC, NTLA, BMRN and ITCI, which are scheduled to report on Feb 22.

Moderna (MRNA) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.

Al Jazeera has called 2023 “the year of the layoffs.” As the news organization pointed out recently, it started badly in 2023, when Salesforce (NYSE: CRM ) cut 10% of its global staff.

Investors' focus will likely be on updates on Moderna's (MRNA) pipeline, especially its late-stage pipeline candidates, when it reports fourth-quarter earnings.

The market is closed for Presidents Day on Monday. Then, Nvidia earnings, FOMC minutes, February Purchasing Managers' Indexes, and more.

Let us look at some drug/biotech stocks, MRNA, BMRN, AMRN, NTLA and BEAM, which are poised to beat on fourth-quarter earnings.

The latest trading day saw Moderna (MRNA) settling at $85.95, representing a +0.68% change from its previous close.

In a time when AI is a friend and a guide through complex financial markets, AI-driven insights provide delight and optimism. Let us begin a deep dive into how ChatGPT, a sophisticated AI model, can g

Hedge funds with long/short strategies have benefited in 2024 from a macroeconomic environment that has hit the most heavily shorted stocks particularly hard compared to their less shorted rivals, a n

The unpredictable nature of the biotech industry, which frequently flirts with failure, underscores the inherent risks and rewards associated with doomed biotech stocks. The journey from drug discover